We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Teva Announces FDA Acceptance of NDA for SD-809 for Huntington Disease Treatment

News   Aug 17, 2015

 
Teva Announces FDA Acceptance of NDA for SD-809 for Huntington Disease Treatment
 
 
Advertisement
 

RELATED ARTICLES

A Long-Acting Injectable Therapy To Treat COVID-19

News

University of Liverpool researchers have demonstrated the potential of repurposing an existing drug called niclosamide into a long-acting injectable therapy that could be used to treat COVID-19.

READ MORE

Denmark To Suspend Rollout of AstraZeneca COVID-19 Vaccine

News

The Danish Health Authority has decided to continue its vaccination programme against COVID-19 without the vaccine from AstraZeneca.

READ MORE

The FDA Calls for Pausing the Use of the Johnson & Johnson COVID-19 Vaccine

News

The United States Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) have recommended pausing the use of the Johnson & Johnson (Janssen) COVID-19 vaccine. In addition, Janssen has declared that it will "proactively delay" the rollout of the vaccine in Europe.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE